diabetestalk.net

Humalog Administration

Insulin Lispro (intravenous Route, Subcutaneous Route)

Insulin Lispro (intravenous Route, Subcutaneous Route)

Description and Brand Names Drug information provided by: Micromedex US Brand Name Humalog Lispro-PFC Descriptions Insulin lispro is a fast-acting type of insulin. Insulin is one of many hormones that help the body turn the food we eat into energy. This is done by using the glucose (sugar) in the blood as quick energy. Also, insulin helps us store energy that we can use later. When you have diabetes mellitus, your body cannot make enough or does not use insulin properly. So, you must take additional insulin to regulate your blood sugar and keep your body healthy. This is very important as too much sugar in your blood can be harmful to your health. Insulin lispro starts to work faster than some other types of insulin, and its effects do not last as long. It should act more like the insulin your body would normally produce. Because the effects of insulin lispro are short-acting, your doctor may also prescribe a longer-acting insulin for you to use. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Suspension Copyright © 2017 Truven Health Analytics Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Continue reading >>

Insulin Lispro: A Fast-acting Insulin Analog

Insulin Lispro: A Fast-acting Insulin Analog

Research has established the importance of maintaining blood glucose levels near normal in patients with type 1 (insulin-dependent) diabetes mellitus. Short-acting insulin analogs are designed to overcome the limitations of regular short-acting insulins. Compared with regular human insulin, the analog insulin lispro offers faster subcutaneous absorption, an earlier and greater insulin peak and a more rapid post-peak decrease. Insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, and peak levels occur 30 to 90 minutes after administration. Duration of activity is less than five hours. Rates of insulin allergy, lipodystrophy, hypoglycemia and abnormal laboratory test results are essentially the same in patients using insulin lispro and in those using regular human insulin. The Diabetes Control and Complications Trial (DCCT)1 established the importance of maintaining near-normal blood glucose levels in patients with type 1 (insulin-dependent) diabetes mellitus. In these patients, intensive therapeutic regimens have been found to delay the onset and reduce the progression of microvascular complications by 50 to 75 percent as compared with conventional regimens. Although no large-scale investigations have been completed, smaller studies have reported similar benefits for intensive therapeutic regimens in patients with type 2 (non–insulin-dependent) diabetes.2 Primary care physicians provide medical care for 75 percent of children and 90 to 95 percent of adults with diabetes.3 Regardless of the type of diabetes, improved glycemic control often can be achieved with individualized tools for patient self-management, carefully formulated nutrition plans and the use of alternative insulin regimens.4 Overview of Insulin Insulin is necessary Continue reading >>

Admelog, Humalog (insulin Lispro) Dosing, Indications, Interactions, Adverse Effects, And More

Admelog, Humalog (insulin Lispro) Dosing, Indications, Interactions, Adverse Effects, And More

100 units/mL (Humalog KwikPen; Humalog Junior KwikPen 3mL pen or cartridge) KwikPen dose increment: 1 unit; maximum dose/injection is 60 units Junior KwikPen dose increment: 0.5 unit; maximum dose/injection is 30 units Rapid-acting human insulin analogue indicated to improve glycemic control in adults and children with type 1 or 2 diabetes mellitus Usual daily maintenance range is 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day Intermediate- or long-acting insulin: Approximately one-third of the total daily insulin requirements SC Rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements Intermediate- or long-acting insulin: 10 units/day SC (or 0.1-0.2 unit/kg/day) at bedtime generally recommended Short-acting insulin: If necessary, start up to 4 units, 0.1 unit/kg SC within 15 min before each meal, or 10% basal dose; if A1C <8%, consider decreasing basal insulin dose by same amount Increase by 1-2 units or 10-15% qWeek or q2Weeks once self-monitoring of blood glucose (SMBG) is achieved (ADA guidelines 2018) Dose adjustment and increased frequency of glucose monitoring Coadministration of drugs that increase the risk of hypoglycemia, and drugs that may increase or decrease blood glucose lowering effects Renal and hepatic impairment: May increase risk for hypoglycemia Do not mix SC injection with insulin preparations other than NPH insulin Do not mix IV or continuous SC infusions with any other insulins Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration; the markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia Do NOT perform dose conversion when u Continue reading >>

Humalog Dosage

Humalog Dosage

Important Administration Instructions Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen. Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. HUMALOG U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. HUMALOG Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix HUMALOG U-200 with any other insulins. Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer HUMALOG U-200 intravenously. Route of Administration Subcutaneous Injection: HUMALOG U-100 or U-200 Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. Continuous Subcutaneous Infusion (Insulin Pump): HUMALOG U-100 ONLY Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump. Administer HUMALOG U-100 by continuous subcutaneous infusion into the subcutaneous tissue of the abdominal wall. Rotate infusion sites within the same region to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)]. Follow healthcare professional recommendati Continue reading >>

U.s. Food And Drug Administration Approves Humalog Insulin Pen

U.s. Food And Drug Administration Approves Humalog Insulin Pen

The U.S. Food and Drug Administration (FDA) has approved Humalog 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. Humalog U-200 KwikPen holds twice as many units of insulin (600 units vs. 300 units) as the U-100 formulation in the same three-milliliter cartridge. This offers patients a pen that lasts longer between pen changes, allowing for fewer changes every month.* Humalog U-200 KwikPen delivers the same dose in half the volume of Humalog U-100 KwikPen with no dose conversions required, and can be dialed in one-unit increments to a maximum of 60 units per injection. "Diabetes is a progressive disease that often requires increased doses of insulin over time to better control a patient's blood sugar levels," said David Kendall, M.D., vice president, Medical Affairs, Lilly Diabetes. "Humalog U-200 KwikPen represents a new option for people with diabetes. Fewer pen changes per month may help people who require higher daily doses of mealtime insulin better fit their treatment in their daily lives." Approval was based on a demonstration of the bioequivalence of Humalog 200 units/mL relative to Humalog 100 units/mL in a pharmacokinetic/pharmacodynamic study. The most common side effect of Humalog is hypoglycemia (low blood sugar) that may be severe and cause unconsciousness, seizures and death. See the Important Safety Information at the end of this press release, Prescribing Information, and Patient Information. "We are proud to advance o Continue reading >>

Humalog (insulin Lispro) 200 Units/ml: Administration

Humalog (insulin Lispro) 200 Units/ml: Administration

Independent Research Clinical Trial Investigational Drugs You are now leaving the LillyMedical.com Web site The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit. Click "Continue" to proceed or "Return" to return to LillyMedical.com. You are now leaving the LillyMedical.com Web site The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit. Click "Agree" to proceed or "Cancel" to return to LillyMedical.com. Continue reading >>

About Fast-acting Mealtime Insulin

About Fast-acting Mealtime Insulin

What is mealtime insulin? Mealtime insulins are fast-acting insulins that are taken immediately before or after meals. As you eat, your blood sugar naturally goes up, or “spikes.” Humalog® (a fast-acting insulin) works to manage those blood sugar spikes and may help keep your sugar levels in balance. Humalog should be taken within 15 minutes before eating or right after eating a meal. People who take Humalog will usually continue to take longer-acting insulin to help manage blood sugar levels at night and between meals. Taking mealtime insulin in addition to longer-acting insulin may help to control blood sugar levels throughout the day. Low blood sugar (hypoglycemia) is the most common side effect of Humalog that may be severe and cause unconsciousness (passing out), seizures, and death. Test your blood sugar levels as your doctor instructs. Talk to your doctor about low blood sugar symptoms and treatment. The orange area shows how blood sugar levels typically rise after meals. The pattern of insulin action may vary in different individuals or within the same individual. Comparing types of insulin Take a look at our overview below to find out about the different types of insulin. You’ll notice that there are differences in when the types of insulin reach your bloodstream, when they “peak” in your body, and how long they can last (length of time the insulin keeps lowering your blood sugar). Fast-acting insulin (also called rapid-acting) is absorbed quickly and starts working in about 15 minutes to lower blood sugar after meals. Humalog fast-acting insulin should be taken 15 minutes before eating or right after eating a meal. Depending on the type of diabetes you have, you may need to take Humalog with a longer-acting insulin or oral anti-diabetes medication. Continue reading >>

Rapid-acting Analogues

Rapid-acting Analogues

Rapid-Acting Analogues Short-Acting Insulins Intermediate-Acting Insulins Long-Acting Insulins Combination Insulins Onset: 12 - 18 min Peak: 1-3 hours Duration: 3-5 hours Solution: Clear Comments: NovoLog should generally be given immediately before a meal (start of meal within 5-10 minutes after injection) because of its fast onset of action. NovoLog is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28 (beta chain). Insulin lispro (Humalog) and insulin aspart (Novolog), when administered intravenously, show pharmacodynamic parameters similar to regular insulin. Mixing NPH: If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first. The injection should be made immediately after mixing. Regular insulin: Compatible - but NO support clinically for such a mixture. Draw up Novolog first before drawing up Regular Insulin. Mixtures should not be administered intravenously. When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent. When rapid-acting insulin is mixed with either an intermediate- or long-acting insulin, the mixture should be injected within 15 min before a meal. INDICATIONS AND USAGE Treatment of Diabetes Mellitus NovoLog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. DOSAGE AND ADMINISTRATION Dosing NovoLog is an insulin analog with an earlier onset of action than regular human insulin. The dosage of NovoLog must be individualized. NovoLog given by subcutaneous injection should generally be used in regimens with an intermediate or long-acting insulin [see package insert for Warnings and Precautions (5), How Supplied Continue reading >>

What Is Humalog (insulin Lispro)?

What Is Humalog (insulin Lispro)?

Humalog is the brand name for a fast-acting insulin called insulin lispro. Humalog Mix 75/25, and Humalog Mix 50/50, contain mixtures of insulin lispro along with a second form of insulin called lispro protamine. Humalog is a medication used to treat both type 1 diabetes and type 2 diabetes. It works in several ways to lower your blood sugar, including by: Helping certain tissues in the body to store glucose in their cells Preventing the liver from producing more glucose Blocking breakdown of fats and proteins Helping to control the overall production and breakdown of sugar in the body The Food and Drug Administration (FDA) first approved Humalog in 1996. Humalog Warnings You shouldn't take Humalog if: You're allergic to Humalog or any of its inactive ingredients Your blood sugar is currently very low Also, it's never a good idea to share your insulin with another person. This includes sharing your Humalog KwikPen, or any insulin pens and insulin cartridges, regardless of whether you've changed needles. Ask your doctor about Humalog if you: Suffer from low blood sugar Have low levels of potassium in your blood Have kidney or liver problems Have heart failure Are taking thiazolidinediones (TZDs), like rosiglitazone-containing drugs such as Avandia, Avandryl, or Avandamet; or drugs that contain pioglitazone, like Actos, Actoplus Met, or Oseni Some insulin products can be mixed together, but Humalog isn't one of them. Never mix Humalog with any other insulins, even if you're using a form of Humalog that comes automatically mixed. Diabetes is a disease that's characterized by high blood sugar, which doctors refer to as hyperglycemia. In type 2 diabetes, the two main contributors to high blood sugar are insulin resistance and a drop in your body's production of insulin. Thes Continue reading >>

Assessment Of The Safety Of Sar342434 And Humalog When Administered As Continuous Subcutaneous Insulin Infusion

Assessment Of The Safety Of Sar342434 And Humalog When Administered As Continuous Subcutaneous Insulin Infusion

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessment of the Safety of SAR342434 and Humalog When Administered as Continuous Subcutaneous Insulin Infusion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT02603510 Information provided by (Responsible Party): Assess the safety of SAR342434 and Humalog when used in external pumps. Incidence of insulin pump alarms for infusion set occlusion. Patient observation of infusion set occlusion. Adverse events including bruising at the infusion site and injection site reactions. The study duration for each patient will be approximately 10 weeks. A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM) SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. Frequency of infusion set occlusions [TimeFrame:4 weeks] Number of infusion set changes in each treatment period [TimeFrame:4 weeks] Number of insulin pump alarms for infusion set occlusions [TimeFrame:4 weeks] Number of adverse events [TimeFrame:4 weeks] Study Description Study Design Arms and Interventions Outcome Measures Eligibil Continue reading >>

U.s. Food And Drug Administration Approves Humalog® 200 Units/ml Kwikpen®

U.s. Food And Drug Administration Approves Humalog® 200 Units/ml Kwikpen®

INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company (NYSE: LLY) announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. Humalog U-200 KwikPen holds twice as many units of insulin (600 units vs. 300 units) as the U-100 formulation in the same three-milliliter cartridge. This offers patients a pen that lasts longer between pen changes, allowing for fewer changes every month.* Humalog U-200 KwikPen delivers the same dose in half the volume of Humalog U-100 KwikPen with no dose conversions required, and can be dialed in one-unit increments to a maximum of 60 units per injection. "Diabetes is a progressive disease that often requires increased doses of insulin over time to better control a patient's blood sugar levels," said David Kendall, M.D., vice president, Medical Affairs, Lilly Diabetes. "Humalog U-200 KwikPen represents a new option for people with diabetes. Fewer pen changes per month may help people who require higher daily doses of mealtime insulin better fit their treatment in their daily lives." Approval was based on a demonstration of the bioequivalence of Humalog 200 units/mL relative to Humalog 100 units/mL in a pharmacokinetic/pharmacodynamic study. The most common side effect of Humalog is hypoglycemia (low blood sugar) that may be severe and cause unconsciousness, seizures and death. See the Important Safety Information at the end of this press release, Prescribing Infor Continue reading >>

Insulin Lispro

Insulin Lispro

Insulin lispro, sold under the brand name Humalog among others, is a fast acting insulin analog. It was first approved for use in the United States in 1996, making it the first insulin analog to enter the market.[2] Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allows larger amounts of active monomeric insulin to be immediately available for postprandial injections.[3] Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin (e.g. NPH insulin) for good glycemic control. Medical uses[edit] Insulin lispro is an FDA approved drug used to treat people living with Type 1 diabetes or Type 2 diabetes.[4] Insulin lispro has non-FDA labeled uses for diabetic neuropathy prevention and cardiovascular disease prevention.[4] Side effects[edit] Common side effects include skin irritation at the site of injection, hypoglycemia, hypokalemia, and lipodystrophy.[4] Other serious side effects include anaphylaxis, and hypersensitivity reactions.[4] Contraindications[edit] Do not administer insulin lispro during episodes of hypoglycemia, or if the patient has a hypersensitivity to insulin lispro or any of its excipients.[4] Cost[edit] In the United States as of 2015 the cost is between 10.06 and 29.36 USD per 100 units.[5] In Europe the price is far lower. The cost in the UK is between £1.66 (about $2.50) and £1.9 Continue reading >>

Insulin Lispro Injection

Insulin Lispro Injection

Insulin lispro is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) who need insulin to control their diabetes. In patients with type 1 diabetes, insulin lispro is always used with another type of insulin, unless it is used in an external insulin pump. In patients with type 2 diabetes, insulin lispro may be used with another type of insulin or with oral medication(s) for diabetes. Insulin lispro is a short-acting, man-made version of human insulin. Insulin lispro works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes. Insulin lispro comes as a solution (liquid) and a suspension (liquid Continue reading >>

Indications And Usage For Humalog

Indications And Usage For Humalog

Generic Name: insulin lispro Dosage Form: injection, solution Humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Dosage and Administration Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)]. Inspect Humalog visually before use. It should appear clear and colorless. Do not use Humalog if particulate matter or coloration is seen. Do NOT mix Humalog U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)]. Do NOT perform dose conversion when using any Humalog U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. Humalog U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. Humalog Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix Humalog U-200 with any other insulins. Do NOT administer Humalog U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer Humalog U-200 intravenously. Route of Administration Subcutaneous Injection: Humalog U-100 or U-200 Administer the dose of Humalog U-100 or Humalog U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. Humalog administered by subcutaneous injection should generally be used in regimens with an intermediate- or lon Continue reading >>

Insulin Lispro (rx)

Insulin Lispro (rx)

Dosage Forms & Strengths Type 1 or 2 Diabetes Mellitus Rapid-acting human insulin analogue indicated to improve glycemic control in adults and children with type 1 or 2 diabetes mellitus Usual daily maintenance range is 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day Intermediate- or long-acting insulin: Approximately one-third of the total daily insulin requirements SC Rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements Type 2 diabetes mellitus Intermediate- or long-acting insulin: 10 units/day SC (or 0.1-0.2 unit/kg/day) at bedtime generally recommended Short-acting insulin: If necessary, start up to 4 units, 0.1 unit/kg SC within 15 min before each meal, or 10% basal dose; if A1C <8%, consider decreasing basal insulin dose by same amount Increase by 1-2 units or 10-15% qWeek or q2Weeks once self-monitoring of blood glucose (SMBG) is achieved (ADA guidelines 2018) Dosing Considerations Do not mix SC injection with insulin preparations other than NPH insulin Do not mix IV or continuous SC infusions with any other insulins Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration; the markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia Do NOT perform dose conversion when using either the Humalog U-100 or U-200 KwikPens; the dose window shows number of insulin units to be delivered and no conversion is needed Do NOT mix Humalog U-200 with any other insulins Do NOT administer Humalog U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump); insulin pump is to be used only for Humalog U-100 Do NOT administer Humalog U-200 intravenousl Continue reading >>

More in insulin